COVID-19 in hematopoietic cell transplant recipients

In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients ( n  = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with h...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2021-04, Vol.56 (4), p.952-955
Main Authors: Altuntas, Fevzi, Ata, Naim, Yigenoglu, Tugce Nur, Bascı, Semih, Dal, Mehmet Sinan, Korkmaz, Serdal, Namdaroglu, Sinem, Basturk, Abdulkadir, Hacıbekiroglu, Tuba, Dogu, Mehmet Hilmi, Berber, İlhami, Dal, Kursat, Erkurt, Mehmet Ali, Turgut, Burhan, Ulgu, Mustafa Mahir, Celik, Osman, Akunal, Abdullah, Birinci, Suayip
Format: Article
Language:English
Subjects:
692/308/174
692/499
692/699/1541/1990
Cancer
Cancer patients
Cell Biology
Comorbidity
Coronaviruses
Correspondence
COVID-19
COVID-19 - mortality
Diagnosis
Hematologic Neoplasms - complications
Hematologic Neoplasms - mortality
Hematological diseases
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Hospitalization
Humans
Immunosuppressive agents
Immunosuppressive Agents - administration & dosage
Internal Medicine
Malignancy
Medicine
Medicine & Public Health
Pandemics
Physiological aspects
Public Health
Stem cell transplantation
Stem Cells
Transplant Recipients
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients ( n  = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT ( n  = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer ( n  = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-020-01084-x